Vyne Therapeutics Inc. 8-K Filing
Ticker: VYNE · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1566044
| Field | Detail |
|---|---|
| Company | Vyne Therapeutics Inc. (VYNE) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vyne Therapeutics Inc. (ticker: VYNE) to the SEC on Dec 12, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (e on which registered Common Stock, $0.0001 par value VYNE The Nasdaq Stock Mar).
How long is this filing?
Vyne Therapeutics Inc.'s 8-K filing is 2 pages with approximately 631 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 631 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2025-12-12 16:01:06
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value VYNE The Nasdaq Stock Mar
Filing Documents
- tm2533382d1_8k.htm (8-K) — 34KB
- 0001104659-25-120637.txt ( ) — 195KB
- vyne-20251212.xsd (EX-101.SCH) — 3KB
- vyne-20251212_lab.xml (EX-101.LAB) — 33KB
- vyne-20251212_pre.xml (EX-101.PRE) — 22KB
- tm2533382d1_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On December 12, 2025, VYNE Therapeutics Inc. (the " Company ") held its 2025 annual meeting of stockholders (the " Annual Meeting "). The stockholders considered three proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 12, 2025 (the " Proxy Statement "). Of the 33,286,422 shares outstanding as of the record date, 16,680,776 shares, or 50.1%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. Proposal No. 1 : The election of two nominees to serve as Class I directors to hold office until the 2028 annual meeting of stockholders and until their respective successors are elected. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes Elisabeth Sandoval Little 3,929,275 1,373,631 11,377,870 Steven Basta 3,903,835 1,399,071 11,377,870 All nominees were elected. Proposal No. 2 : Ratification of the selection by the audit committee of the board of directors of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: Votes For Votes Against Abstentions Ratification of appointment of Baker Tilly US, LLP 15,296,776 766,080 617,920 Proposal No. 3 : Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. The Company's stockholders approved the compensation of the Company's named executive officers. The votes were cast as follows: Votes For Votes Against Abstentions Broker Non-Votes Advisory approval of named executive officer compensation 4,566,359 680,945 55,602 11,377,870
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYNE THERAPEUTICS INC. Date: December 12, 2025 /s/ Mutya Harsch Mutya Harsch Chief Legal Officer and General Counsel